Pembrolizumab (Keytruda) for unresectable or metastatic melanoma
HAYES, Inc.
Record ID 32016000792
English
Authors' recommendations:
Description of Technology: Pembrolizumab is a fully human monoclonal immunoglobulin G4 antibody to the programmed death 1 (PD-1) transmembrane receptor that is borne by cancer cells, including melanoma and non-small cell lung cancer. PD-1 is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer cells. Pembrolizumab binds to PD-1, preventing it from interacting with its ligands and permitting activated T cells to attack tumor cells. The recommended dose is 2 milligrams per kilogram administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity. Like other antibodies to immune checkpoint molecules, pembrolizumab is associated with immune-related adverse events.
Patient Population: Pembrolizumab is indicated for the treatment of patients with unresectable or metastatic melanoma.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=41126
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Melanoma
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.